A new study from our team, published in JAMA Network Open (October 2025), shows that open-label placebos (OLPs)—placebos honestly described as such—can meaningfully improve quality of life in people with migraine when added to standard preventive treatment. While OLPs did not reduce headache frequency, patients receiving OLPs reported less pain-related disability and felt significantly better overall. These findings, led by Julian Kleine-Borgmann and Katharina Schmidt, and conducted in collaboration with the Frankfurt Headache Center within the DFG-funded CRC 289 Treatment Expectation, suggest that OLPs may represent an ethical and safe add-on option to enhance patient-centered migraine care. Read the full article in JAMA Network Open